Scottish Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, EH16 4UU, UK.
BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, EH16 4TJ, UK.
Int J Mol Sci. 2019 Apr 29;20(9):2123. doi: 10.3390/ijms20092123.
Brugada syndrome is an inherited, rare cardiac arrhythmogenic disease, associated with sudden cardiac death. It accounts for up to 20% of sudden deaths in patients without structural cardiac abnormalities. The majority of mutations involve the cardiac sodium channel gene and give rise to classical abnormal electrocardiogram with ST segment elevation in the right precordial leads V1 to V3 and a predisposition to ventricular fibrillation. The pathophysiological mechanisms of Brugada syndrome have been investigated using model systems including transgenic mice, canine heart preparations, and expression systems to study different mutations. These models have a number of limitations. The recent development of pluripotent stem cell technology creates an opportunity to study cardiomyocytes derived from patients and healthy individuals. To date, only a few studies have been done using Brugada syndrome patient-specific iPS-CM, which have provided novel insights into the mechanisms and pathophysiology of Brugada syndrome. This review provides an evaluation of the strengths and limitations of each of these model systems and summarizes the key mechanisms that have been identified to date.
Brugada 综合征是一种遗传性、罕见的心律失常性疾病,与心脏性猝死相关。它占无结构性心脏异常患者心脏性猝死的 20%。大多数突变涉及心脏钠离子通道基因,并导致经典异常心电图,表现为右胸导联 V1 至 V3 的 ST 段抬高和易发生心室颤动。Brugada 综合征的病理生理机制已通过包括转基因小鼠、犬心制剂和表达系统在内的模型系统进行了研究,以研究不同的突变。这些模型有许多局限性。多能干细胞技术的最新发展为研究源自患者和健康个体的心肌细胞提供了机会。迄今为止,只有少数使用 Brugada 综合征患者特异性 iPS-CM 的研究已经完成,这些研究为 Brugada 综合征的机制和病理生理学提供了新的见解。这篇综述对这些模型系统的优缺点进行了评估,并总结了迄今为止确定的关键机制。